WO2016059602A3 - Méthodes de traitement du cancer et compositions associées - Google Patents

Méthodes de traitement du cancer et compositions associées Download PDF

Info

Publication number
WO2016059602A3
WO2016059602A3 PCT/IB2015/057947 IB2015057947W WO2016059602A3 WO 2016059602 A3 WO2016059602 A3 WO 2016059602A3 IB 2015057947 W IB2015057947 W IB 2015057947W WO 2016059602 A3 WO2016059602 A3 WO 2016059602A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen binding
binding proteins
combination therapy
treat cancer
her3
Prior art date
Application number
PCT/IB2015/057947
Other languages
English (en)
Other versions
WO2016059602A2 (fr
Inventor
Neil James Clarke
Rakesh Kumar
Biju MANGATT
Christopher MATHENY
Yong Yu
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of WO2016059602A2 publication Critical patent/WO2016059602A2/fr
Publication of WO2016059602A3 publication Critical patent/WO2016059602A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines de liaison à un antigène, telles que des anticorps, qui se lient à HER3, des polynucléotides codant pour ces protéines de liaison à un antigène, des compositions pharmaceutiques comprenant lesdites protéines de liaison à un antigène, et des procédés de fabrication. La présente invention porte en outre sur l'utilisation de ces protéines de liaison à un antigène dans le traitement ou la prophylaxie de maladies associées au cancer du sein, des ovaires, de la prostate, de la vessie, du pancréas, et de l'estomac, au mélanome et à d'autres types de cancer surexprimant HER3.
PCT/IB2015/057947 2014-10-16 2015-10-15 Méthodes de traitement du cancer et compositions associées WO2016059602A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462064559P 2014-10-16 2014-10-16
US62/064,559 2014-10-16
US201562121639P 2015-02-27 2015-02-27
US62/121,639 2015-02-27

Publications (2)

Publication Number Publication Date
WO2016059602A2 WO2016059602A2 (fr) 2016-04-21
WO2016059602A3 true WO2016059602A3 (fr) 2016-06-09

Family

ID=54477033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/057947 WO2016059602A2 (fr) 2014-10-16 2015-10-15 Méthodes de traitement du cancer et compositions associées

Country Status (1)

Country Link
WO (1) WO2016059602A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
BR112013004266A8 (pt) 2010-08-23 2018-01-02 Univ Texas anticorpos anti-ox40 e métodos de uso dos mesmos.
MX2016010082A (es) 2014-02-04 2016-10-07 Pfizer Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
IL278423B2 (en) 2015-02-26 2024-04-01 Merck Patent Gmbh Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR20180015650A (ko) 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
WO2016205277A1 (fr) 2015-06-16 2016-12-22 Merck Patent Gmbh Polythérapies faisant intervenir un antagoniste de pd-l1
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
KR20180083944A (ko) 2015-12-02 2018-07-23 아게누스 인코포레이티드 항체 및 이의 사용 방법
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
JP6729926B2 (ja) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法
AU2017339856A1 (en) 2016-10-06 2019-05-23 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10311977B2 (en) 2017-02-16 2019-06-04 Huff & Enterprises, LLC Proactive disease state management system
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
WO2018225034A1 (fr) * 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Polythérapie avec un agoniste icos et un agoniste ox40 pour traiter le cancer
AU2020284288A1 (en) * 2019-05-27 2022-01-20 Promis Neurosciences Inc. Conformation-specific epitopes in tau, antibodies thereto and methods related thereof
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
US20230029157A1 (en) * 2019-11-26 2023-01-26 The Regents Of The University Of California Combination therapy for head and neck cancer
MX2022008412A (es) 2020-01-07 2022-08-08 Univ Texas Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2161336A1 (fr) * 2005-05-09 2010-03-10 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
WO2011011027A1 (fr) * 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combinaison d’un anticorps anti-ctla-4 avec divers régimes de traitement pour le traitement synergique de maladies prolifératives
WO2012031198A2 (fr) * 2010-09-03 2012-03-08 Glaxo Group Limited Nouvelles protéines de liaison à un antigène
WO2013071058A1 (fr) * 2011-11-09 2013-05-16 The Uab Research Foundation Anticorps her3 et utilisations de ceux-ci
WO2014083178A1 (fr) * 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification de patients ayant besoin d'une cothérapie par un inhibiteur de pd-l1

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2119930C (fr) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production d'anticorps chimeres - demarche combinatoire
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (fr) 1992-08-17 1994-03-03 Avi J. Ashkenazi Immunoadhesines bispecifiques
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU743616B2 (en) 1997-02-07 2002-01-31 Merck & Co., Inc. Synthetic HIV gag genes
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (fr) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
CA2421447C (fr) 2000-09-08 2012-05-08 Universitat Zurich Groupes de proteines a domaines de repetition comprenant des modules de repetition
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2838062C (fr) 2001-08-03 2015-12-22 Roche Glycart Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
WO2003014161A2 (fr) 2001-08-10 2003-02-20 Aberdeen University Domaines de liaison d'antigenes
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
CA2832136C (fr) 2002-09-27 2015-11-17 Xencor Variants fc optimises et methodes destinees a leur generation
CA2512729C (fr) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
DK1641818T3 (da) 2003-07-04 2009-03-16 Affibody Ab Polypeptider der har bindingsaffinitet for HER2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1711196A4 (fr) 2003-12-05 2011-09-14 Bristol Myers Squibb Co Inhibiteurs des recepteurs du facteur de croissance endothelial vasculaire de type 2
ES2297723T3 (es) 2004-06-11 2008-05-01 Japan Tobacco, Inc. Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido(2,3-d)pirimidina y compuestos relacioandos para el tratamiento de cancer.
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP1776385A1 (fr) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2
EP1921090B1 (fr) 2005-07-22 2015-01-14 Kyowa Hakko Kirin Co., Ltd. Composition d'anticorps genetiquement modifie
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
US7883430B2 (en) 2008-07-22 2011-02-08 Nike, Inc. Releasable and interchangeable connections for golf club heads and shafts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2161336A1 (fr) * 2005-05-09 2010-03-10 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
WO2011011027A1 (fr) * 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combinaison d’un anticorps anti-ctla-4 avec divers régimes de traitement pour le traitement synergique de maladies prolifératives
WO2012031198A2 (fr) * 2010-09-03 2012-03-08 Glaxo Group Limited Nouvelles protéines de liaison à un antigène
WO2013071058A1 (fr) * 2011-11-09 2013-05-16 The Uab Research Foundation Anticorps her3 et utilisations de ceux-ci
WO2014083178A1 (fr) * 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification de patients ayant besoin d'une cothérapie par un inhibiteur de pd-l1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. MIRSCHBERGER ET AL: "RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation", CANCER RESEARCH, vol. 73, no. 16, 15 August 2013 (2013-08-15), US, pages 5183 - 5194, XP055239599, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-13-0099 *
J. B. FITZGERALD ET AL: "MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 2, 1 February 2014 (2014-02-01), US, pages 410 - 425, XP055218661, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-13-0255 *
N. JIANG ET AL: "Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 7, 18 April 2014 (2014-04-18), US, pages 1826 - 1836, XP055239604, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-13-1093 *

Also Published As

Publication number Publication date
WO2016059602A2 (fr) 2016-04-21

Similar Documents

Publication Publication Date Title
WO2016059602A3 (fr) Méthodes de traitement du cancer et compositions associées
MX2013002535A (es) Nuevas proteinas de union a antigenos.
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
EA201891366A1 (ru) Гуманизированные антитела против cd73
NZ738008A (en) Tigit-binding agents and uses thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
GEP20237466B (en) Methods of inhibiting angiogenesis in patient
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500890A1 (en) Antibody drug conjugates
EP3964527A3 (fr) Polythérapie contre le cancer
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
NZ603271A (en) Anti-erbb3 antibodies
MX2015013203A (es) Conjugados de anticuerpo - farmaco.
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
JOP20170063B1 (ar) أجسام مضادة لـ TNF- a وشظايا وظيفية منها
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
TN2018000298A1 (en) ANTl-TNFALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PL3720879T3 (pl) Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15791034

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15791034

Country of ref document: EP

Kind code of ref document: A2